Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Genprex, Inc.'s (GNPX) shares rose 9.5% after it announced the expansion of the Acclaim-3 clinical study of lead cancer candidate, Reqorsa, to additional trial sites.Under collaboration with a large network of community-based oncology practices, Genprex is adding multiple clinical study sites for the early to mid-stage combination study of Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) to treat patients with extensive-stage small cell lung cancer (ES-SCLC). Reqorsa has been developed utilizing its pr ...